Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$25.99 - $33.85 $111,757 - $145,555
-4,300 Reduced 45.26%
5,200 $139,000
Q1 2024

May 15, 2024

SELL
$27.11 - $35.17 $138,261 - $179,367
-5,100 Reduced 34.93%
9,500 $324,000
Q4 2023

Feb 14, 2024

BUY
$22.72 - $29.68 $288,544 - $376,936
12,700 Added 668.42%
14,600 $422,000
Q3 2023

Nov 14, 2023

SELL
$27.57 - $32.91 $13,785 - $16,455
-500 Reduced 20.83%
1,900 $52,000
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $41,874 - $54,221
1,400 Added 140.0%
2,400 $72,000
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $27,944 - $33,624
800 Added 400.0%
1,000 $36,000
Q4 2022

Feb 14, 2023

BUY
$31.09 - $37.88 $6,218 - $7,576
200 New
200 $7,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.02B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.